![Tassos Gianakakos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tassos Gianakakos
No open positions remaining
Net worth: 204 M $ as of 31/07/2026
Profile
Currently, Anastasios E. Gianakakos holds the position of Chief Executive Officer for MyoKardia, Inc. He is also on the board of LianBio. In the past Mr. Gianakakos was President & Senior VP-Business Development at Codexis, Inc., Process Engineer at Merck & Co., Inc., Director -Business Development at Maxygen, Inc. and Chief Business Officer & Senior Vice President at MAP Pharmaceuticals LLC. He received an undergraduate degree from Massachusetts Institute of Technology, a graduate degree from Northwestern University and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
10.53% | 18/06/2026 | 9,806,633 ( 10.53% ) | 204 M $ | 31/07/2026 |
LIANBIO 0.35% | 15/02/2024 | 363,253 ( 0.35% ) | 17 472 $ | 31/07/2026 |
Tassos Gianakakos active positions
| Companies | Position | Start |
|---|
Former positions of Tassos Gianakakos
| Companies | Position | End |
|---|---|---|
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Operates as a patient-centered clinical intelligence company dedicated to cardiology research and care ecosystem | Chief Executive Officer | 01/02/2025 |
| LIANMEDICAL | Director/Board Member | 01/03/2024 |
| MYOKARDIA, INC. | Chief Executive Officer | 01/11/2020 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Corporate Officer/Principal | 01/03/2013 |
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 01/01/1997 |
Training of Tassos Gianakakos
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
64
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LianBio
 LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Operates as a patient-centered clinical intelligence company dedicated to cardiology research and care ecosystem | Health Technology |
- Stock Market
- Insiders
- Tassos Gianakakos
